2025-01-10
Verdiva launches with $410M for weight loss drugs to challenge Ozempic, Wegovy
London-headquartered biotech startup Verdiva has emerged from stealth with a whopping $410mn for a new range of drugs aimed at tackling the obesity epidemic. It’s one of Europe’s largest-ever biotech VC deals, signalling investor appetite for the booming weight loss market. Verdiva looks to challenge the dominance of Novo Nordisk and Eli Lilly, the makers of the two most popular weight loss drugs, Ozempic and Wegovy. The company promises to offer less invasive pills, instead of injectables. Its most advanced product is an oral [...]
Rating
Innovation
Pricing
Technology
Usability
We have discovered similar tools to what you are looking for. Check out our suggestions for similar AI tools.
2025-05-30
How Ozempic maker Novo Nordisk fell behind Eli Lilly in the weight loss drug race
Novo Nordisk (NVO) makes Ozempic, the best-known GLP-1 drug out today. And until quite recently, the Danish pharma giant consistently led the pack in new prescriptions, becoming virtually synonymous w [...]
2025-03-07
Wegovy's price cut, Amgen's Ozempic competitor, and Big Pharma's tax cut: Pharma news roundup
Novo Nordisk just cut the price of its weight-loss drug, Wegovy, by more than half for patients who pay without insurance. Amgen (AMGN) announced this week that it has begun two late-stage clinical tr [...]
2025-05-20
Noom is offering microdoses of compounded Wegovy for weight loss
Noom will start offering microdoses of compounded Wegovy (NVO), the blockbuster weight-loss drug, as the digital health company continues to adapt to the growing demand for affordable weight-loss solu [...]
2025-04-30
Weight loss drugs can help employers cut health care costs, study says
Covering the cost of pricey GLP-1 weight loss drugs could pay off for employers by cutting overall medical spending for people taking the medications, but not until year two, according to a massive a [...]
2025-04-23
Eli Lilly is stepping up its fight against copycat weight-loss drugs
In its continuing war against copycat drugs, Eli Lilly (LLY) said on Wednesday that it filed suits against four telehealth companies that offer cheaper versions of its blockbuster GLP-1 weight loss dr [...]
2025-05-16
Novo Nordisk's CEO is out after the Ozempic maker's stock dropped 50% in a year
Novo Nordisk (NVO) CEO Lars Fruergaard Jørgensen will step down after eight years at the helm of the Danish pharmaceutical giant responsible for the blockbuster drugs Ozempic and Wegovy, the company [...]